To investigate the effects of nimotuzumab on circulating Treg and NK cells of HNSCC patients, the frequency of CD4+CD25+CD39+Foxp3+Treg and CD56+CD16+ NK cells in PBMC was analyzed before and after therapy. This evidence concerns the gene FCGR3A and head and neck squamous cell carcinoma.